Company

NeuroTherapia, Inc.

NeuroTherapia develops small molecule treatments for neuroinflammatory diseases, including Alzheimer's disease.

About

Founded in 2015 and based in Cleveland, US, NeuroTherapia develops oral medicines targeting microglia and other drivers of central nervous system inflammation. Its lead program, NTRX-07, is being developed for Alzheimer's disease. In August 2024, it raised USD 12.3 million in Series B funding led by Cleveland Clinic Ventures.

2Funding rounds

3Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in